

The Cancer Center Newsletter

3 ISSUE
2010



NYHQ Receives Commission on Cancer Reaccreditation with Commendation

The New York Hospital Queens Cancer Center has been granted a three-year accreditation with commendation by the Commission on Cancer (CoC) of the American College of Surgeons.

NYHQ's program was specially recognized with **commendations in eight areas**, including community outreach programs related to cancer screenings and prevention, clinical services and cancer data management.

Continued on page 2

Inside this Issue:

2

New Radiation Oncologist at NYHQ Studying Impact of Asian Ethnicity on Radiation Treatment Outcomes for Nasopharyngeal Cancer

3

The 7th Annual NYHQ Thoracic Symposium

4

Gerald J. Wang, M.D.
Director, Division of Urology,
Department of Surgery

Cancer Center Program
Leadership

5

Theresa Lang Research
Center, Cancer Related
Studies

Recent Events



A higher level of cancer care.
Right here in Queens.

THE
CANCER CENTER

member
NewYork-Presbyterian
Healthcare System
affiliate: Weill Cornell Medical College

Dattatreya Nori, M.D.,
F.A.C.R., F.A.C.R.O., Director
of the Cancer Center, Chairman,
Department of Radiation
Oncology at NYHQ, and
Professor and Radiation Oncologist
in Chief at NewYork-Presbyterian
Hospital, Weill Medical College of
Cornell University.

The Cancer Center Newsletter

(cont. from page 1)

About The NYHQ Cancer Center

NYHQ's Cancer Center has been dedicated to providing top-notch cancer care to the residents of Queens and the surrounding communities. The Cancer Center has experienced, board certified surgeons, medical oncologists, radiation oncologists and radiologists, as well as other highly qualified health care professionals, to provide the best standard of care available to cancer patients.

In addition, cancer patients can access psychosocial services through various cancer support groups and patient navigators. NYHQ's Cancer Center also works with the American Cancer Society, another resource from which patients and their families can research and receive information about cancers and treatments.

About Commission on Cancer Approval

Commission on Cancer accreditation is received by only one in four hospitals that treat cancer patients, and is given only to those

facilities that have voluntarily committed to provide the best in diagnosis and treatment of cancer. NYHQ has maintained COC Approval since 1987.

Receiving care at a Commission on Cancer accredited facility ensures that, most importantly, patients receive quality care. A CoC-Approved Cancer Program has the resources to ensure that patients have access to comprehensive care, including a range of state-of-the-art services and equipment; a multi-specialty team approach to coordinate the best treatment options available to cancer patients; cancer-related information, education and support; lifelong patient follow-up through a cancer registry that collects data on types and stages of cancers and treatment results; and information about ongoing clinical trials and new treatment options.

CoC Approval is widely recognized by national organizations, such as the Joint Commission on Accreditation of Healthcare Organizations and the American Cancer Society.

New Radiation Oncologist at NYHQ Studying Impact of Asian Ethnicity on Radiation Treatment Outcomes for Nasopharyngeal Cancer

Baoqing Li, M.D., Ph.D. attending physician in the Department of Radiation Oncology at New York Hospital Queens, will be presenting his study on nasopharyngeal cancer among Asian subgroups at the American Society for Radiation Oncology (ASTRO) Annual Meeting in November in San Diego, California. ASTRO holds the largest international meeting in Radiation Oncology.

Nasopharyngeal cancer (NPC) is one of the most common cancers among Asians, but rare among non-Asians. Dr. Li became interested in this cancer during his residency, when he also volunteered every month and performed free cancer screening for those Asian patients who do not have insurance at the Paul Hom Asian Clinic, the oldest existing Asian clinic in the US. He noticed some significant difference in clinical outcomes of NPC, even among Asians from different regions. Based on this observation, Dr. Li started doing research using the California Cancer Registry. California has 12% of the population of the United States, including 36% of all U.S. Asians. From 1988 to 2007, a total of 3923 new cases of NPC were identified and were classified into 4 ethnic categories: Chinese, South East Asian (SEA), North East Asian (NEA), and non-Hispanic White (NHW). The results are very

promising: among Chinese patients the proportion of World Health Organization (WHO) 2/3 histology, cancer-specific survival, and overall survival are significantly higher than those in the SEA group, while those in the NEA and NHW had the worst clinical outcomes. More importantly, Dr. Li showed that even among those with WHO2/3 histology, Chinese patients did better than those from SEA or NEA groups. This finding challenges the "common sense" hypothesis that Chinese NPC patients do better than others simply due to the higher proportion of Chinese patients with WHO2/3 histology, which is more sensitive to radiation treatment. The identification of Chinese ethnicity as another independent and favorable prognostic factor for survival indicates possible underlying differences in EBV carcinogenesis or tumor biology. Dr. Li hopes to continue his study of NPC in Asian subgroups at NYHQ, where a significant number of Asian NPC patients have been treated and there is a well-maintained patient database in the NYHQ Cancer Center Registry.

Dr. Li was raised in Shanghai, China where he completed his college education. He came to the U.S. and obtained a Ph.D. degree in molecular biology from the University of Miami, followed by an M.D. degree from New York Medical College.

(cont. on page 3)

The 7th Annual NYHQ Thoracic Symposium

Advances in Treatment of Lung Cancer and Benign Thoracic Disorders

Tuesday, November 9, 2010
8:00 am–1:00 pm

New York Hospital Queens
Theresa and Eugene M. Lang Center
for Research and Education
56-45 Main Street
Flushing, NY 11355

For registration fees and program information:

Ms. Pamela Williams
Director, Continuing Medical Education

Tel: 718-670-1419

Fax: 718-661-7925

Email: pgw9001@nyp.org

www.nyhqme.org

Statement of Need

Lung cancer remains the most common cause of cancer death in the United States. Chest wall disorders, both malignant and benign, are not well understood and often, treatment for these disorders is unrecognized. Recent advances in diagnosis and treatment have considerably improved the outlook for these patients. This 7th New York Hospital Queens Thoracic Symposium will review current trends and advances in the diagnosis and treatment of these disorders for primary care physicians and all others involved in the care of thoracic patients. The new staging system for lung cancer will be presented, as well as newer bronchoscopic diagnostic and staging methods. Controversies in the management of stage IIIA lung cancer will be discussed. Treatment for pectus excavatum and hypoventilation syndromes will be presented. An evidence-based review of the role of medical and surgical therapy in the treatment of these disorders will be presented.

This symposium will address these key and often controversial issues in the diagnosis and treatment of lung cancer and chest wall disorders.

3.25 AMA PRA

Category 1 Credit(s)[™]

Nursing credit pending

Educational Objectives

The purpose of this program is to improve patient care. At the conclusion of this program, participants will be able to improve patient outcomes through:

- 1 Understanding the new lung cancer staging system and recognizing important changes from the prior system.
- 2 Awareness of new bronchoscopic diagnostic and staging modalities.
- 3 Understanding the controversies in the management of stage IIIA lung cancer.
- 4 Identifying thymic disorders and understanding the algorithms of care.
- 5 Recognizing benign chest wall deformities and understanding the appropriate workup and treatment for these patients.
- 6 Understanding the role of medical and surgical interventions in hypoventilation syndromes.

Program Co-Chairs

Subroto Paul, M.D.
Paul C. Lee, M.D.
Stephen Karbowitz, M.D.

Faculty

Matthew Bacchetta, M.D.
Jeffrey Cole, M.D.
Bryan J. Schneider, M.D.
Brendon M. Stiles, M.D.

(cont. from page 2)

He has a special interest in molecular cancer biology and was recently honored with the prestigious Young Oncologist Essay Award from the American Radium Society for his research on the role of microRNA in radiation resistant prostate cancer. For more information please visit the following link:

http://www.ucdmc.ucdavis.edu/radonc/highlights/highlights_BaoqingLi.html

Dr. Li's special interests in Radiation Oncology include head and neck malignancy, thoracic malignancy and genitourinary malignancy.



Gerald J. Wang, M.D.
Director, Division of Urology,
Department of Surgery

Gerald Wang, M.D. has joined NYHQ as the Director of the Division of Urology. Dr. Wang comes to NYHQ from the New York Presbyterian Hospital, Weill Medical College of Cornell University,

where he completed a Fellowship in Urologic Oncology and Robotic Surgery. Dr. Wang is a graduate of Yale University with a bachelor of science degree in Molecular Biophysics & Biochemistry. He received his medical degree from the Stanford University School of Medicine, and he completed his urology residency at the New York Presbyterian Hospital, Weill Medical College of Cornell University.

Dr. Wang has published numerous articles in national and international urologic journals, as well as book chapters in

urology textbooks. He has presented extensively at international urologic meetings and has won several awards, most notably for his research in robotic surgery. Recently, he was appointed as the prestigious Ferdinand C. Valentine Research Fellow by the New York Academy of Medicine - N.Y. Section of the American Urological Association for his work in bladder cancer research. He is noted for publishing one of the seminal papers on the role of robotic surgery for removal of the bladder for invasive bladder cancer. While he is trained in all aspects of general urology, Dr. Wang has particular expertise in cancers of the genitourinary tract, including prostate, bladder, kidney and testis cancers. As a fellowship-trained urologic oncologist, he also has specialized training in minimally invasive urologic surgery, including laparoscopy and robotic surgery for renal, bladder and prostate tumors. Dr. Wang is Clinical Assistant Professor of Urology at Weill Medical College of Cornell University and a member of the American Urological Association and Society for Laparoendoscopic Surgeons.

CANCER CENTER CLINICAL PROGRAM LEADERSHIP

DIRECTOR

Dattatreya Nuri, M.D., F.A.C.R., F.A.C.R.O. 670-1501

ASSOCIATE DIRECTOR

Mitchell Chorost, M.D. 670-1120

BREAST CENTER

Karen Karsif, M.D. 670-1185

Susan Lee, M.D.

Margaret Chen, M.D.

COLORECTAL SURGERY

Howard Tiszenkel, M.D. 445-0220

GASTROINTESTINAL, MEDICAL

Moshe Rubin, M.D. 670-2559

GYNECOLOGIC ONCOLOGY

Marie Welshinger, M.D. 670-1170

Manolis Tsatsas, M.D.

HEAD AND NECK ONCOLOGY

Jerry Huo, M.D. 670-0006

MEDICAL ONCOLOGY

Barry Kaplan, M.D., Ph.D. 460-2300

NEUROSURGERY

Jaime Nieto, M.D. 670-1837

Murisiku Raifu, M.D.

PALLIATIVE CARE

Simon Fink, M.D. 670-1120

PULMONARY MEDICINE

Stephen Karbowitz, M.D. 670-1405

RADIATION ONCOLOGY

Dattatreya Nuri, M.D. 670-1501

RADIOLOGY

William Wolff, M.D. 670-1594

SURGICAL ONCOLOGY

Mitchell Chorost, M.D. 670-1120

SURGICAL PATHOLOGY

Michael Warhol, M.D. 670-1141

Stanley Kerpel, D.D.S. (*Oral Pathology*) 670-1520

THORACIC SURGERY

Paul Lee, M.D. 670-2707

Subroto Paul, M.D.

UROLOGY

Gerald J. Wang, M.D. For Physicians: 670-1097

For Patients: 445-0220

GENETIC COUNSELING

Kayon Williams, M.S. 670-2110

NUTRITION

Jack Pasquale, M.D. 465-0041

Mary Grace Sucholet, R.D. 670-2550

PAIN MANAGEMENT

Peter Silverberg, M.D. 670-1080

Vikas Varma, M.D. 460-1111

Ji Han, M.D. 460-2300

SOCIAL SERVICE

Marlene Smike 670-1300

CANCER RESEARCH

Engracio Cortes, M.D. 279-9101

Baoqing Li, M.D., Ph.D. 670-1501

ADMINISTRATION

Maureen Buglino, R.N., M.P.H.,

Vice President, Ambulatory Services 670-1981

Tom Deutsch, M.P.H., M.B.A., *Administrative Director* 670-1501

Vijaya Malladi, C.T.R., *Manager* 670-1379

Theresa Lang Research Center, Cancer Related Studies (as of August 2010)

TITLE	PRINCIPAL INVESTIGATOR	STATUS	DEPARTMENT NAME
Breast MRI in Pre-menopausal Women Diagnosed with Breast Cancer	Lee, Susan H. M.D.	Active	Surgery
Gastric Cancer Incidence and Prevalence in a Younger Population in our Community Hospital	Somnay, Kaumudi A. M.D.	Active	Medicine
Identification and Isolation of Breast Cancer-Specific Biomarkers in Tissue and Biological Fluids	Lee, Susan H. M.D.	Active	Surgery
Treatment Patterns and Outcomes of Elderly Breast Center Patients Age 75 or Older	Ravi, Akamma M.D.	Active	Radiation Oncology
Disparities in Radiotherapy for Breast Cancer and Ductal Carcinoma In Situ: Survey	Lee, Susan H. M.D.	Active	Surgery
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND#70177) versus no Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy (GOG-212)	Tsatsas, Manolis M.D.	Active	OB/GYN
A Prospective Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer undergoing primary Chemotherapy (GOG-0235)	Tsatsas, Manolis M.D.	Active	OB/GYN
Breast Cancer and Anxiolytic effects of Reiki during Radiation Therapy	Ravi, Akamma M.D.	Active	Radiation Oncology
A Molecular Staging Study of Endometrial Carcinoma (GOG 210)	Tsatsas, Manolis M.D.	Active	OB/GYN
A Multi-Site Prospective, Non-randomized Study Utilizing the Contura Multi-lumen Balloon (MLB) Breast Brachytherapy Applicator to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetric Success, Local Tumor Control, Cosmetic Outcome, Acute and Chronic Toxicity, and Clinical Scenarios for Optimal Use	Ravi, Akamma M.D.	Active	Radiation Oncology
The Applicability of Breast Cancer Normogram in Predicting Nonsentinel Lymph Node Status In a Population ≥ 70 years of Age	Lee, Susan H. M.D.	Active	Surgery
Prognostic Factor & Treatment Outcomes in Non-Metastatic Uterine Sarcomas	Ravi, Akamma M.D.	Active	Radiation Oncology
Laparoscopic vs. Open Resection for Rectal Cancer: A NSQIP Analysis	Tiszenkel, Howard M.D.	Active	Surgery
Utility of Stool Occult Blood Test as a Screening Modality to Detect Gastric Cancer in the High-Risk Population	Somnay, Kaumudi A. M.D.	Active	Medicine
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin v. Ifosfamide Plus Paclitaxel in Chemotherapy Naive Patients With New Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma of Uterus	Tsatsas, Manolis M.D.	Active	OB/GYN
A Phase III Trial of Pelvic Radiation Therapy vs. Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma	Tsatsas, Manolis M.D.	Active	OB/GYN
A Phase III Clinical Trial of Bevacizumab with IV vs. IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma	Tsatsas, Manolis M.D.	Active	OB/GYN
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel v. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Cancer	Tsatsas, Manolis M.D.	Active	OB/GYN
Ductal Carcinoma In-Situ: Prognostic factors and treatment outcome in younger women	Ravi, Akamma M.D.	Active	Radiation Oncology
Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination w/ Doxorubicin & Cyclophosphamide (TAC) v Doxorubicin & Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast CA Negative Patients with Positive Lymph Node	Kaplan, Barry H. M.D.	Closed to Enrollment	Medicine
Impact of Breast Specimen Sonogram on Re-Excision Rates after Breast Conserving Surgery Cancer	Sung, Kap Jae M.D.	New From PI	Surgery

RECENT EVENTS

Paul Freedman, D.D.S., Director, Section of Oral Pathology in the Department of Dentistry at NYHQ has been elected Vice President of the American Academy of Oral and Maxillofacial Pathology.

Paul C. Lee, M.D., Vice Chairman of the Department of Cardiothoracic Surgery and Chief of the Thoracic Surgery Division at NYHQ had the following article published:

Sharma B., Reddy M., Lee PC, Cortes G., Gumpeni R. An unusual clinical presentation of a rare renal tumour. *Nephrol Dial Transplant* 2010.

Dr. Lee also presented the following:

Lee PC, Port JL, Paul S., Stiles BM, Saunders J., Christos P., Altorki NK. Predictors of recurrence, time to progression and disease-free survival in patients with completely resected esophageal carcinoma. Presented at the 90th Annual Meeting of The American Association for Thoracic Surgery, Toronto, ON, Canada. May 4, 2010.

Nurkin S., Kakarla V., Chouseleb S., Addasi T., Lee P., Turner JW, Paul S. Early outcome following transhiatal and transthoracic esophagectomy for cancer. Poster presented at 10th Annual Residents and Fellows Research Day, New York Hospital Queens, Flushing, NY, May 12, 2010.

Dr. Lee was an invited lecturer for the following events:

Diagnosis and treatment of lung cancer. Visiting Nurse Service of New York CWCB radio interview. New York, New York, April 14, 2010.

Surgical management of gastric cancer. New York Hospital Queens community outreach program in Flushing Library. Flushing, New York, May 25, 2010.

Management of non-small cell lung cancer. Visiting Nurse Service of New York dinner and lecture program. Flushing, New York, June 17, 2010.

Antigen-Specific Cancer Immunotherapy (ASCI): Phase III Study — MAGRIT. New York Hospital Queens. Flushing, New York, July 20, 2010.

TUMOR BOARDS/PATIENT CARE CONFERENCES

The **Department of Radiation Oncology** has **New Patient Conferences** every Tuesday morning at 8 a.m.

Breast Tumor Board is held on the second and fourth Wednesday of every month from 12 p.m. to 1 p.m. Lunch is served. Next upcoming dates are October 13 and 27th.

Thoracic Tumor Board is on the third Wednesday of every month from 9 a.m. to 10 a.m. Next date is October 6th.

Gyn Tumor Board is held on the first Wednesday of every month from 8 a.m. to 9 a.m. Next upcoming date is October 6th.

General Tumor Board is held every Tuesday from 4 p.m. to 5 p.m. There is one Continuing Medical Education (CME) credit awarded per each Tumor Board meeting attended.

All the above noted professional educational programs are held in the **Anarena M. Anextis Conference Room** in the **Department of Radiation Oncology**. Refreshments are served.

PATIENT SUPPORT GROUPS

The American Cancer Society sponsors a **"Man-to-Man"** program for **prostate cancer** patients, on the second Wednesday of every month from 6 p.m. to 7:30 p.m. and a **"Look Good-Feel Better"** program for **female cancer patients undergoing Chemotherapy and Radiation Therapy** on the second Monday of every month from 5:30 p.m. to 6:30 p.m. For registration please call 1-800-ACS-2345.

The Leukemia and Lymphoma Society sponsors a Caregivers Support Group to address the unique needs of friends and relatives of those who care for others with any type of cancer diagnosis on the first Wednesday of every month at 6 p.m. To register, please call 212-376-4772.

A smoking Cessation Support Group is held the first Thursday of every month at 11 a.m. Contact the NYHQ Department of Health Outreach at 718-670-1211.

The above programs are held in the **Anarena M. Anextis Conference Room** in the **Department of Radiation Oncology**.

nyhq.org

New York Hospital Queens
56-45 Main Street, Flushing, NY 11355-5095

member
NewYork-Presbyterian
Healthcare System
affiliated: Weill Cornell Medical College



THE
CANCER CENTER



A higher level of cancer care.
Right here in Queens.